OverviewSuggest Edit

PerkinElmer provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets. The Company operates in two segments, Discovery and Analytical Solutions, and Diagnostics. The Discovery and Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions.

TypePublic
Founded1931
HQWaltham, US
Websiteperkinelmer.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Dec 2019)13,000(+4%)
Job Openings342
Revenue (FY, 2019)$2.9 B(+4%)
Share Price (Sept 2020)$119.8 (+2%)
Cybersecurity ratingBMore

PerkinElmer Office Locations

PerkinElmer has offices in Waltham, Akron, American Fork, Billerica and in 16 other locations
Waltham, US (HQ)
940 Winter St
Akron, US
520 S Main St #2502
American Fork, US
732 E 930 S #120
Billerica, US
331 Treble Cove Rd, North Billerica
Boston, US
549 Albany St
Branford, US
29 Business Park Dr
Show all (20)

PerkinElmer Financials and Metrics

PerkinElmer Revenue

PerkinElmer's revenue was reported to be $2.88 b in FY, 2019
USD

Revenue (FY, 2019)

2.9b

Net income (FY, 2019)

227.6m

EBIT (FY, 2019)

362.0m

Market capitalization (25-Sept-2020)

13.4b

Closing stock price (25-Sept-2020)

119.8

Cash (29-Dec-2019)

191.9m

EV

15.4b
PerkinElmer's current market capitalization is $13.4 b.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.1b2.2b2.2b2.3b2.1b2.3b2.8b2.9b

Revenue growth, %

3%1%(6%)7%

Cost of goods sold

763.0m1.1b1.2b1.4b

Gross profit

1.4b1.0b1.1b1.3b
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017Q3, 2018Q2, 2019Q3, 2019

Revenue

510.9m521.8m509.6m505.4m543.3m674.3m722.5m706.9m

Cost of goods sold

278.9m283.0m278.9m280.5m301.0m342.0m374.7m364.6m

Gross profit

232.0m238.8m230.7m224.9m242.3m332.3m347.8m342.3m

Gross profit Margin, %

45%46%45%44%45%49%48%48%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2019

Cash

171.4m173.2m174.8m237.9m359.3m202.1m191.9m

Accounts Receivable

457.0m470.0m470.6m439.0m425.6m552.3m725.2m

Prepaid Expenses

95.6m100.4m

Inventories

247.7m288.0m246.8m351.7m356.9m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017Q3, 2018Q2, 2019Q3, 2019

Cash

144.8m171.4m170.8m125.9m112.5m132.3m224.1m205.3m203.7m168.9m195.1m192.2m311.7m210.7m248.1m288.3m616.3m149.5m150.0m393.0m

Accounts Receivable

407.9m389.5m394.9m410.8m434.8m428.5m443.0m443.7m427.0m415.4m414.2m425.7m443.3m436.8m435.8m411.1m440.4m551.4m654.5m646.3m

Prepaid Expenses

103.4m92.3m113.6m100.3m99.8m110.4m119.0m117.3m

Inventories

251.9m244.4m261.4m259.8m259.5m278.4m279.0m278.0m281.6m291.1m313.0m304.8m306.0m314.1m300.3m264.6m275.1m354.2m414.3m391.8m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

69.9m167.2m157.8m212.4m234.3m292.6m237.9m227.6m

Depreciation and Amortization

126.9m128.5m116.7m112.0m100.0m105.0m180.6m214.0m

Inventories

(8.2m)(17.9m)(30.2m)(9.6m)

Accounts Payable

(7.9m)(1.8m)8.1m(16.1m)30.7m34.3m8.9m7.4m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q3, 2018Q2, 2019Q3, 2019

Net Income

22.6m56.2m85.8m32.2m60.1m100.3m34.2m84.7m127.0m40.3m54.9m49.0m58.1m47.5m63.9m38.6m166.6m104.5m163.1m

Depreciation and Amortization

32.0m64.2m94.8m30.6m62.8m96.5m29.4m57.9m86.8m133.4m103.8m157.1m

Inventories

(13.0m)(12.7m)(24.4m)(16.2m)(17.5m)(31.8m)(17.7m)(15.7m)(28.5m)313.0m304.8m306.0m314.1m300.3m264.6m(41.3m)(50.4m)(48.4m)

Accounts Payable

(11.7m)1.6m(18.6m)4.9m3.5m(6.0m)904.0k(11.9m)(4.0m)149.7m170.7m162.3m159.5m156.4m158.1m(36.6m)(40.0m)(34.0m)
USDQ1, 2013

Financial Leverage

2.1 x
Show all financial metrics

PerkinElmer Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

PerkinElmer Revenue Breakdown

Embed Graph

PerkinElmer revenue breakdown by business segment: 69.9% from Discovery & Analytical Solutions and 30.1% from Diagnostics

PerkinElmer revenue breakdown by geographic segment: 62.9% from International and 37.1% from U.S.

PerkinElmer Online and Social Media Presence

Embed Graph

PerkinElmer News and Updates

PerkinElmer Launches Solus Listeria monocytogenes ELISA Assay for Testing Across Food and Environmental Samples

This new offering will help high throughput food processors and contract labs focus on L. mono testing for food and environmental surface samples. In sync with leading industry standards, the new solution is being introduced with Performance Tested Method SM (PTM) certification from AOAC® INTERNATIO…

PerkinElmer Introduces AuroFlow AQ Mycotoxin Platform to Support Testing for Top Six Regulated Mycotoxins in Grain Commodities

WALTHAM, Mass -- July 20, 2020 - PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched its AuroFlow® AQ Mycotoxin Platform . This new solution  includes strip test versions for Total Aflatoxin, Deoxynivalenol (DON), Fumonisin, Ochratoxin A, Zearalenone and …

PerkinElmer and American Society of Hematology Announce Global Collaboration to Help Combat Sickle Cell Disease

WALTHAM, Mass., June 18, 2020 /PRNewswire/ -- PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced a collaboration with the American Society of Hematology (ASH), the world's largest professional society of hematologists, to support...

PerkinElmer Launches Pre-eclampsia Kit for Enhanced Management

This kit will enable short term prediction of pre-eclampsia and aid in diagnosis in the second and third trimesters of pregnancy together with the previously launched DELFIA® Xpress PlGF 1-2-3™ assay . It is easily adaptable for current screening customers using the DELFIA® Xpress instrument.read mo…

PerkinElmer gets emergency OK from FDA for coronavirus test

PerkinElmer Inc. said late Tuesday it received an emergency use authorization from the Food and Drug Administration so labs can start using its test for SARS-CoV-2, the virus that causes COVID-19. PerkinElmer shares rose 1% after hours, following a 9.5% rise to finish the regular session at $74.31.…

Stocks making the biggest move after the bell: Whirlpool, F5 Networks, PerkinElmer & more

Take a look at the companies making headlines after the bell.
Show more

PerkinElmer Blogs

PerkinElmer Launches Modular and Scalable explorer™ Workstations for High-throughput COVID-19 Detection

PerkinElmer Launches Modular and Scalable explorer™ Workstations for High-throughput COVID-19 Detection Content Import Mon, 08/17/2020 - 09:00 PerkinElmer Launches Modular and Scalable explorer™ Workstations for High-throughput COVID-19 Detection August 17, 2020 at 9:00 AM E…

PerkinElmer Enhances Hand Sanitizer Analyzer to Detect Methanol in 30 Seconds or Less

Instrument also tests ethanol and isopropanol concentrations to confirm product efficacy WALTHAM, Mass. – August 24, 2020 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its Hand Sanitizer Analyzer instrument can be used to test for the

PerkinElmer Announces Financial Results for the Second Quarter of 2020

Revenue of $811.7 million ; 12% reported growth; 13% organic growth GAAP EPS from continuing operations of $1.23 ; Adjusted EPS of $1.57 WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 28, 2020-- PerkinElmer, Inc . (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported

PerkinElmer Launches Online, Open Access COVID-19 Data Dashboards to Accelerate Antiviral Therapeutics Research

PerkinElmer Launches Online, Open Access COVID-19 Data Dashboards to Accelerate Antiviral Therapeutics Research Liz.McPherson@… Tue, 07/21/2020 - 11:48 PerkinElmer Launches Online, Open Access COVID-19 Data Dashboards to Accelerate Antiviral Therapeutics Research July 22, 20…

PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test

Fully automated kit detects human antibodies of immunoglobulin class IgG to help identify individuals with adaptive immune response WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 21, 2020-- PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the

PerkinElmer Introduces AuroFlow® AQ Mycotoxin Platform to Support Testing for Top Six Regulated Mycotoxins in Grain Commodities

Features water-based testing strips and handheld reader delivering  convenience and accuracy WALTHAM, Mass -- July 20, 2020 - PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched its AuroFlow® AQ Mycotoxin Platform .
Show more

PerkinElmer Frequently Asked Questions

  • When was PerkinElmer founded?

    PerkinElmer was founded in 1931.

  • How many employees does PerkinElmer have?

    PerkinElmer has 13,000 employees.

  • What is PerkinElmer revenue?

    Latest PerkinElmer annual revenue is $2.9 b.

  • What is PerkinElmer revenue per employee?

    Latest PerkinElmer revenue per employee is $221.8 k.

  • Who are PerkinElmer competitors?

    Competitors of PerkinElmer include Agilent, Thermo Fisher Scientific and Bruker.

  • Where is PerkinElmer headquarters?

    PerkinElmer headquarters is located at 940 Winter St, Waltham.

  • Where are PerkinElmer offices?

    PerkinElmer has offices in Waltham, Akron, American Fork, Billerica and in 16 other locations.

  • How many offices does PerkinElmer have?

    PerkinElmer has 20 offices.